Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 3, 2010, Pages 228-234

  Nguyen, Leslie ^a   Zhong, Wei Zhu ^a   Painter, Cory L ^a   Zhang, Cathy ^a   Rahavendran, Sadayappan V ^a   Shen, Zhongzhou ^a  

^a PFIZER INC   (United States)

Author keywords

LC MS MS; PD 0332991; Supported liquid extraction (96 well format); Xenograft mouse tumor tissue

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXPOSURE; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; EXTRACTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; METHODOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCID MOUSE; SUPPORTED LIQUID EXTRACTION; TISSUE HOMOGENATE; TUMOR; TUMOR XENOGRAFT;

ANIMALS; CHROMATOGRAPHY, LIQUID; CYCLIN-DEPENDENT KINASE 4; DRUG STABILITY; FEMALE; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TRANSPLANTATION, HETEROLOGOUS;

EID: 77954861829     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.02.031     Document Type: Article

References (25)

1. Obaya A.J., Sedivy J.M. Regulation of cyclin-CDK activity in mammalian cells. Cell. Mol. Life Sci. 2002, 59:126-142.
2. Morgan D.O., Fisher R.P., Espinoza F.H. Control of eukaryotic cell cycle progression by phosphorylation of cyclin-dependent kinases. Cancer J. Sci. Am. 1998, 4:S77-S83.
3. Sielecki T.M., Boylan J.F., Benfield P.A., Trainor G.L. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. 2000, 43:1-18.
4. Garrett M.D., Fattaey A. CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev. J. Med. Chem. 1999, 9:104-111.
5. Finn R.S., Dering J., Conklin D., Kalous O., Cohen D.J., Desai A.J., Ginther C., Atefi M., Chen I., Fowst C., Los G., Slamon D.J. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009, 11:R77. http://breast-cancer-research.com/content/pdf/bcr2419.pdf.
6. Fry D.W., Harvey P.J., Keller P.R., Elliott W.L., Meade M., Trachet E., Albassam M., Zheng X., Leopold W.R., Pryer N.K., Toogood P.L. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3:1427-1438.
7. Masson E., Zamboni W.C. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin. Pharmacokinet. 1997, 32:324-343.
8. Lin J.H. Tissue distribution and pharmacodynamics: a complicated relationship. Curr. Drug Metab. 2006, 7:39-65.
9. Eichler H.G., Mueller M. Drug distribution. The forgotten relative in clinical pharmacokinetics. Clin. Pharmacokinet. 1998, 34:95-99.
10. Stumpf W.E. Memo to the FDA and ICH: appeal for in vivo drug target identification and target pharmacokinetics. Recommendations for improved procedures and requirements. Drug Discov. Today 2007, 12:594-598.
11. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 2001, 46:149-168.
12. Langer O., Mueller M. Methods to assess tissue-specific distribution and metabolism of drugs. Curr. Drug Metab. 2004, 5:463-481.
13. Galmarini C.M., Galmarini F.C. Multidrug resistance in cancer therapy: role of the microenvironment. Curr. Opin. Investig. Drugs 2003, 4:1416-1421.
14. Zhao M., Hartke C., Jimeno A., Li J., He P., Zabelina Y., Hidalgo M., Baker S.D. Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B 2005, 819:73-80.
15. Savage R.E., Hall T., Bresciano K., Bailey J., Starace M., Chan T.C.K. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ARQ 501 (β-lapachone) in plasma and tumors from nu/nu mouse xenografts. J. Chromatogr. B 2008, 872:148-153.
16. Patel K., Lweiston D., Gu Y., Hicks K.O., Wilson W.R. Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry. J. Chromatogr. B 2007, 856:302-311.
17. Otaegui D., Rodriguez-Gascon A., Zubia A., Cossio F.P., Pedraz J.L. Development and validation of a liquid chromatography-tandem mass spectrometry for the determination of Kendine 91, a novel histone deacetylase inhibitor, in mice plasma and tissues: application to a pharmacokinetic study. J. Chromatogr. B 2008, 870:109-116.
18. Zirrolli J.A., Bradshaw E.L., Long M.E., Gustafson D.L. Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues. J. Pharm. Biomed. Anal. Pharmacol. 2005, 39:705-711.
19. Warnke M.M., Wanigasekara E., Singhal S.S., Singhal J., Awasthi S., Armstrong D.W. The determination of glutathione-4-hydroxynonenal (GSHNE), E-4-hydroxynonenal (HNE), and E-1-hydroxynon-2-en-4-one (HNO) in mouse liver tissue by LC-ESI-MS. Anal. Bioanal. Chem. 2008, 392:1325-1333.
20. Magnes C., Suppan M., Pieber T.R., Moustafa T., Trauner M., Haemmerle G., Sinner F.M. Validated comprehensive analytical method for quantification of coenzyme A activated compounds in biological tissues by online solid-phase extraction LC/MS/MS. Anal. Chem. 2008, 80:5736-5742.
21. Ito S., Kudo K., Imamura T., Suzuki T., Ikeda N. Sensitive determination of methomyl in blood using gas chromatography-mass spectrometry as its oxime tert.-butyldimethylsilyl derivative. J. Chromatogr. B 1998, 713:323-330.
22. Kaufmann A., Butcher P. Quantitative liquid chromatography/tandem mass spectrometry determination of chloramphenicol residues in food suing sub-2μm particulate high-performance liquid chromatography columns for sensitivity and speed. Rapid Commun. Mass Spectrom. 2005, 19:3694-3700.
23. Williams L., Cleeve M., Merriman S., Lodder H., Jordan S., Calverley R., Smith J. The isolation of three β-blockers from human plasma using Isolute SLE+ supported liquid extraction 96-well plate. LC GC Europe 2007, 26-27.
24. O'Maille G., Pai S.M., Tao X., Douglas G.T., Jenkins R.G. An improved LC-ESI-MS-MS method for simultaneous quantitation of rosiglitazone and N-desmethyl rosiglitazone in human plasma. J. Pharm. Biomed. Anal. 2008, 48:934-939.
25. Jiang H., Jiang X., Ji Q.C. Enantioselective determination of alprenolol in human plasma by liquid chromatography with tandem mass spectrometry using cellubiohydrolase chiral stationary phases. J. Chromatogr. B 2008, 872:121-127.